Sexual Health Supplements Market By Product Type (Libido Enhancers, Fertility Support Supplements, Erectile Function Supplements, Menopause and Hormonal Health Supplements, Stamina Boosters); By Gender (Men, Women, Unisex); By Distribution Channel (Online Platforms, Pharmacies, Specialty Retailers, Grocery Stores, Clinics); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Sexual Health Supplements Market Growth Outlook  – (Updated On: 14-Aug-2026)

The Global Sexual Health Supplements Market was valued at USD 4.2 billion in 2025 and is projected to reach USD 7.7 billion by 2032, growing at a CAGR of 8.5% during 2026–2032, according to Strategic Market Research.

 

Sexual health supplements are ingestible products formulated for libido, fertility, erectile function, menopause-related wellness, hormonal health and sexual stamina. The category includes vitamins, minerals, botanicals, amino acids, capsules, tablets, gummies, powders and other nutritional formulations.

 

Demand is increasing as sexual wellness becomes more closely connected with fertility planning, women's health, menopause and healthy aging. Consumers are also moving from general enhancement products toward formulations developed for specific needs and life stages.

 

Libido enhancers remain the largest product category with a 31% share, while fertility support is the fastest-growing at a 9.4% CAGR. Online platforms lead distribution with a 38% share and are also the fastest-growing channel at 10.6%. Women represent the fastest-growing gender segment at 9.1%, showing how the market is broadening beyond its traditional male-focused base.

 

Can Evidence-Led Formulations and Non-Pill Formats Reshape the Sexual Health Supplements Market?

The Sexual Health Supplements Market is shifting toward more targeted formulations built around circulation, stress management and sexual wellness, while safety scrutiny is increasing sharply. Nitric-oxide-related ingredients such as L-arginine and L-citrulline are gaining attention because of their roles in vascular function. Clinical reviews have found signals of benefit for some nutraceuticals, including L-arginine, but the strength of evidence varies considerably by ingredient and formulation.

Adaptogens are creating another formulation pathway. Ashwagandha is increasingly incorporated into products positioned around stress, libido and male sexual health. A 2026 randomized, double-blind, placebo-controlled study evaluated ashwagandha root extract specifically for sexual health in healthy men, adding to the emerging clinical evidence base. However, such findings should not be generalized to every commercial ashwagandha supplement.

At the same time, consumers are gaining non-pill alternatives. Eroxon (MED3000), for example, became the first FDA-authorized over-the-counter gel for erectile dysfunction in 2023. It is a non-medicated medical device rather than a dietary supplement, illustrating how the broader sexual-wellness market is diversifying beyond capsules and tablets. Investigational products are exploring additional pathways: LIB-01 is currently being studied in a Phase 2a trial for erectile dysfunction, but it is an experimental drug candidate, not a supplement.

The biggest market constraint remains product integrity and regulation. FDA does not approve dietary supplements for safety and effectiveness before they reach consumers. More significantly, the FDA listed 23 sexual-enhancement product notifications between February 11 and August 12, 2026 alone, involving potentially harmful hidden ingredients. Some tested products contained undeclared sildenafil or tadalafil, which can interact dangerously with nitrate medications and cause severe blood-pressure reductions.

Consequently, clinically supported ingredients, transparent labeling, third-party quality controls and safer non-pill formats are becoming increasingly important competitive differentiators in the Sexual Health Supplements Market.

 

What Are the Advancements in Sexual Health Supplements and Clinical Integration Trends?

Recent developments in sexual health supplements are increasingly centered on combination protocols that integrate low-dose prescription medications with standardized herbal ingredients such as ginseng and L-citrulline, aiming to enhance efficacy while reducing dependency on pharmaceuticals. This approach is supported by growing clinical interest in botanical aphrodisiacs and stricter evaluation of over-the-counter nutraceutical safety. Research is also advancing toward structured integration and tapering strategies, where low-dose PDE5 inhibitors are paired with herbal extracts to maintain sexual performance while minimizing side effects, followed by gradual dose reduction under supervision.

Scientific focus has expanded into mechanistic studies of botanicals, identifying active compounds like coumarin derivatives and Panax ginseng that influence hormonal pathways and nitric oxide production. Amino acids such as L-arginine and L-citrulline are also being studied for their role in improving vascular function and endothelial health rather than relying on generalized libido enhancement claims.

At the same time, safety and quality control remain critical priorities, with increased regulatory scrutiny targeting unlabelled pharmaceutical adulterants found in some over-the-counter sexual enhancement products. Medical guidance continues to emphasize professional consultation, as unregulated formulations may lead to cardiovascular risks or harmful interactions with existing medications, reinforcing the need for clinically validated and transparently formulated supplements.

 

Why Is Demand for Sexual Health Supplements Increasing?

Demand is expanding because sexual wellness now intersects with three large health needs: reproductive planning, age-related sexual function and women's midlife health.

WHO estimates that about one in six people of reproductive age worldwide experience infertility during their lifetime. In the United States, CDC data published in December 2025 show that 13.7% of women aged 20–49 had used fertility services, including testing, fertility drugs, insemination and assisted reproductive technology. These figures provide a substantial underlying population for preconception and fertility-focused nutritional products.

Men's sexual health provides another large demand pool. NIDDK estimates that 30–50 million men in the United States have erectile dysfunction, with prevalence increasing with age. Sexual-health supplements do not replace clinically indicated treatments, but the scale of the affected population creates continuing interest in products positioned around sexual wellness, vitality and erectile-function support.

The wider supplement culture also lowers the barrier to adoption. The Council for Responsible Nutrition's 2024 Ipsos survey found that 75% of U.S. adults use dietary supplements, indicating that supplement consumption is already embedded in mainstream wellness routines.

 

Which Sexual Health Supplement Product Type Leads the Market?

Libido enhancers are the largest category, accounting for 31% of the market or USD 1.302 billion in 2025, with an 8.2% CAGR. Their position reflects broad relevance across both male and female sexual wellness. Mainstream supplement brands are also entering the category; OLLY, for example, offers a dedicated women's libido formulation containing ingredients such as ashwagandha.

Fertility support holds 23%, equivalent to USD 0.966 billion, and is the fastest-growing product category at 9.4%. Growth is moving beyond female prenatal nutrition toward separate male and female reproductive-health products. Theralogix markets ConceptionXR specifically for male reproductive health, while Fairhaven Health offers distinct FertilAid formulations for men and women. This broadens fertility supplementation from a female-only category into couple-based reproductive wellness.

Erectile-function supplements account for 21%, or USD 0.882 billion, with a 7.8% CAGR. The segment has a large potential user base but also faces the strongest product-safety concerns. In May 2026, FDA laboratory testing found undeclared sildenafil, tadalafil and testosterone propionate in Erectus Plus, a product promoted for male sexual enhancement. FDA maintains an active notification page covering similar products.

Menopause and hormonal health represent 15%, or USD 0.630 billion, and are growing at 9.2%. This segment is becoming strategically important as supplement companies build dedicated menopause portfolios. Bonafide Health launched Noctera in February 2026 as a non-prescription supplement positioned around menopause-related sleep difficulties, expanding its existing women's midlife-health portfolio.

Stamina boosters hold 10%, valued at USD 0.420 billion, with a 7.3% CAGR. Growth is slower because stamina formulations overlap with broader energy and performance supplements. Strong performance claims can also attract additional safety scrutiny, particularly when products are marketed online.

 

Why Are Women's Sexual Health Supplements Growing Faster?

Women account for 39% of the market, or USD 1.638 billion in 2025, and have the fastest gender CAGR at 9.1%. Growth comes from several categories simultaneously, including fertility support, libido, menopause and hormonal wellness.

Industry investment confirms the increasing strategic importance of this segment. Pharmavite acquired Bonafide Health for USD 425 million in November 2023, adding a specialist women's-health business centered on menopause and related health needs.

Bonafide then moved beyond its direct-to-consumer model in September 2025, placing four products in more than 1,800 Target stores and Target.com. The expansion shows that menopause-focused supplements are moving from specialist online channels into mainstream retail.

Men remain the largest gender segment at 45%, worth USD 1.890 billion, with an 8.1% CAGR. Demand spans libido, erectile function, fertility and stamina. Male fertility is gaining visibility as brands such as Theralogix and Fairhaven Health market dedicated reproductive-health products for men.

Unisex supplements hold 16%, or USD 0.672 billion, and are growing at 8.3%. They remain relevant for general vitality and wellness, although targeted male and female products provide clearer positioning for fertility, menopause and erectile-function needs.

 

Which Distribution Channel Is Growing Fastest?

Online platforms are both the largest and fastest-growing distribution channel, representing 38% of 2025 revenue or USD 1.596 billion and expanding at a 10.6% CAGR.

Sexual wellness fits digital retail particularly well because online stores provide privacy, broader product selection and convenient repeat ordering. Specialized fertility and menopause brands can also reach consumers without depending entirely on limited physical shelf space. Bonafide's transition from a primarily direct-to-consumer model into Target.com and more than 1,800 physical Target stores illustrates how leading brands are increasingly combining digital reach with mainstream retail availability.

Pharmacies hold 27%, worth USD 1.134 billion, with a 7.2% CAGR. Their health-focused setting and accessibility maintain their relevance, particularly for recognized supplement brands.

Specialty retailers account for 15%, or USD 0.630 billion, and grow at 7.8%. Their strength lies in wider access to botanical and targeted wellness formulations, although they face increasing competition from online stores.

Grocery represents 11%, or USD 0.462 billion, with a 6.5% CAGR. The channel remains better suited to widely recognized wellness products than specialized sexual-health formulations.

Clinics account for 9%, valued at USD 0.378 billion, and grow at 7.4%. Their strongest connection is with fertility and preconception care. CDC's finding that 13.7% of U.S. women aged 20–49 had used fertility services indicates a sizable population interacting with reproductive-health professionals.

 

How Do Regulation and Product Safety Affect Sexual Health Supplements?

Sexual health supplements are generally regulated as food products rather than prescription medicines in both the United States and Europe, meaning they are not evaluated for safety or effectiveness before reaching consumers. In the United States, these products fall under dietary supplement rules established by the Dietary Supplement Health and Education Act of 1994, which places them within the broader food category. Manufacturers are not required to obtain pre-market approval, allowing products to be sold without prior clinical validation. However, companies are restricted from making disease-treatment claims and may only use general structure-function statements such as supporting stamina or vitality. Regulatory enforcement is largely reactive, with authorities intervening after products enter the market if safety concerns arise or if adulteration with pharmaceutical ingredients is detected.

In the European Union, sexual health supplements are also classified as food supplements, though regulatory oversight varies across member states. While vitamin and mineral limits are harmonized to some extent, herbal and botanical ingredients are subject to inconsistent national rules. The European Food Safety Authority imposes strict scientific requirements for any approved health claims, making marketing claims more tightly controlled than in the U.S. Safety monitoring is supported through systems that track illegal imports and product risks across the region.

Despite these frameworks, the market faces ongoing safety challenges, particularly the illegal addition of prescription drug ingredients in unregulated products and the ease of distribution through online channels, which increases consumer exposure to potentially unsafe supplements.

 

Which Companies Are Competing in the Sexual Health Supplements Market?

Pharmavite / Bonafide Health: Strategic Leader in Women’s Sexual Wellness & Menopause Supplements Market Growth
Pharmavite strengthened its position in women's sexual and hormonal wellness through the USD 425 million acquisition of Bonafide Health in 2023. Bonafide's portfolio addresses menopause, vaginal health and sexual satisfaction through products including Ristela, Revaree and Relizen. In 2025, the brand expanded into more than 1,800 Target stores and Target.com, moving menopause and intimate-wellness products further into mainstream retail.

OLLY: Mainstream Sexual Wellness Brand Driving Libido Support Through Lifestyle Supplement Innovation
OLLY competes through accessible lifestyle-oriented wellness products, including Lovin' Libido, which is positioned specifically for women's libido, arousal and sexual satisfaction. Its presence within a broader vitamins and supplements portfolio reflects the increasing integration of sexual wellness into everyday consumer health rather than keeping it within a specialist category.

Theralogix: Fertility Nutrition Powerhouse Advancing Male and Female Reproductive Health Supplements
Theralogix has a stronger position in fertility and reproductive nutrition, particularly through its ConceptionXR range for men and TheraNatal products for women. Its fertility portfolio covers sperm health, motility, egg health and preconception nutrition. This positioning aligns closely with fertility support, the fastest-growing product segment in the supplied market data at a 9.4% CAGR.

Fairhaven Health: Dual-Partner Fertility Supplement Brand Targeting Couples’ Reproductive Wellness Needs
Fairhaven Health addresses both male and female fertility through FertilAid and FH PRO formulations. Its FertilAid portfolio includes separate products for men and women as well as bundled options for couples. This approach reflects growing demand for reproductive-health supplementation that considers both partners rather than focusing primarily on female fertility.

Overall, companies are differentiating through condition-specific formulations, women's health expansion, fertility specialization and multichannel availability. The strongest competitive positions are increasingly built around clear product purposes and credible ingredient positioning, particularly as regulatory scrutiny of poorly labeled sexual-enhancement products increases.

 

Where Are the Strongest Regional and Competitive Opportunities?

North America represents the strongest current commercial environment, although regional market shares were not supplied. The region combines high supplement use with sizable fertility and erectile-function needs. Three-quarters of U.S. adults report using supplements, 13.7% of women aged 20–49 have used fertility services and NIDDK estimates that 30–50 million U.S. men have erectile dysfunction.

Europe remains attractive but requires more disciplined health-claim positioning. EU rules governing food supplements and authorized health claims favor products with clear ingredient documentation and compliant communication rather than aggressive performance promises.

Asia-Pacific offers longer-term expansion opportunities but requires country-specific approaches. Australia's continuing enforcement against undeclared medicines demonstrates the scrutiny applied to sexual-enhancement products in developed regional markets. Product classification, permitted ingredients and labeling can also differ considerably by country.

Competition is increasingly centered on specialized, repeat-use wellness portfolios. Pharmavite's Bonafide acquisition and subsequent Target expansion demonstrate growing investment in women's midlife health. OLLY participates through women's libido supplements, while Theralogix and Fairhaven Health have built dedicated male and female fertility portfolios.

The strongest growth opportunity is therefore moving toward fertility, women's sexual wellness, menopause and digitally distributed repeat-use products. The main forecast risk remains product credibility. Brands that combine targeted formulations with transparent ingredients and defensible claims are better positioned as consumers become more selective about sexual-health products.

 

Sexual Health Supplements Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 4.2 Billion
Revenue Forecast in 2032	USD 7.7 Billion
Overall Growth Rate	CAGR of 8.5% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Gender, By Distribution Channel, By Geography
By Product Type	Libido Enhancers, Fertility Support Supplements, Erectile Function Supplements, Menopause and Hormonal Health Supplements, Stamina Boosters
By Gender	Men, Women, Unisex
By Distribution Channel	Online Platforms, Pharmacies, Specialty Retailers, Grocery Stores, Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising consumer focus on sexual wellness and preventive health, growing demand for fertility and menopause-focused supplements, increasing adoption of online wellness platforms and personalized formulations
Customization Option	Available upon request